M
Muvon Therapeutics
Biotech & Life Sciences · Zurich, Switzerland · Founded 2020
Muvon Therapeutics is creating an autologous cell therapy for damaged skeletal muscles in SUI patients, with a primary focus on developing a safe treatment for stress urinary incontinence in women MoreLess
MUVON Therapeutics is a pioneering company in the field of regenerative medicine, focusing on developing innovative therapies for conditions related to skeletal muscle damage or degradation. The company's primary area of focus is treating stress urinary incontinence (SUI) in women, a condition that affects millions worldwide. MUVON Therapeutics aims to support women respectfully throughout their journey to a healthier life.
The core technology of MUVON Therapeutics involves the targeted isolation of muscle precursor cells (MPCs) from muscle tissue. These cells are then expanded in a controlled environment and reintroduced into the patient's body to regenerate damaged muscle tissue. This novel approach has been under research for over 12 years at the University of Zurich's Tissue Engineering and Regenerative Medicine laboratory.
MUVON Therapeutics operates in the healthcare and biotechnology market, serving patients suffering from muscle-related conditions, with an initial focus on women with SUI. The company’s business model revolves around developing and commercializing its regenerative therapy platform. Revenue is generated through clinical trials, partnerships, and eventually, the sale of its proprietary treatment once it gains regulatory approval.
The company has made significant progress in its clinical applications. After receiving approval for a first-in-man trial in 2015, MUVON completed the GMP validation of its patented production process and initiated a Phase I clinical study at the University Hospital of Zurich in January 2020. The first patient was treated in March 2020, and the trial concluded in late 2021. Phase II began in September 2022 and is currently ongoing.
MUVON Therapeutics is an attractive investment opportunity for those interested in cutting-edge regenerative therapies. The company’s leadership team includes experts in both scientific research and business administration, ensuring a balanced approach to innovation and commercialization.
Keywords: Regenerative Therapy, Muscle Damage, Stress Urinary Incontinence, Women’s Health, Biotechnology, Clinical Trials, MPCs, University of Zurich, Healthcare Innovation, Investment Opportunity.
Company overview
Muvon Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Zurich, Switzerland
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 60.4
Valuation & funding
Muvon Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAM✓Other financing | Jan 2022 | $0 | — | Swissnex | — |
| GRANT✓Other financing | May 2021 | $5.5M | — | Horizon 2020 | ↗ |
| SERIES A✓Equity / VC | May 2021 | $14M | $55M | Lichtsteiner Foundation | ↗ |
| SPINOUT✓Other financing | Oct 2020 | $0 | — | University of Zürich | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 16 |
| 2025 | 19 |
| 2024 | 23 |
| 2023 | 19 |
| 2022 | 15 |
Growth signals
Muvon Therapeutics website traffic
Latest recorded traffic for Muvon Therapeutics is 140 monthly website visits, down 90.7% over the last three months. Muvon Therapeutics's team declined 15.8% over the past year.
Comparisons
Muvon Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Muvon Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Muvon Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Muvon Therapeutics has talent and traffic
team presence
In the news
Latest news about Muvon Therapeutics
Recent press, funding announcements, and product moves mentioning Muvon Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Muvon Therapeutics
An AI-synthesized read of the highest-engagement posts about Muvon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Muvon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.